News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Jonathan Licht: How KDM6A controls MHC-I and II expression in multiple myeloma cells
Jonathan Licht/X
Oct 9, 2024, 16:24

Jonathan Licht: How KDM6A controls MHC-I and II expression in multiple myeloma cells

Jonathan Licht, Director of the UF Health Cancer Center, shared a post on X:

“Our paper on how tumor suppressor KDM6A controls MHC-I and II expression in multiple myeloma cells is out in print in Blood Journal.

KDM6A loss can be ameliorated by treatment of cells with an HDAC3 inhibitor, restoring MHC expression.”

KDM6A controls immunogenicity in MM

Authors: Jerome Moreaux.

Jonathan Licht: How KDM6A controls MHC-I and II expression in multiple myeloma cells

 

Blood Journal cancer cancer awareness cancer care Cancer research fight against cancer Global fight against cancer Jerome Moreaux Jonathan Licht Myeloma OncoDaily Oncology
Special Coverage
Insight
Jan 20, 2025, 12:28
Myeloma Paper of the Day, January 20th, suggested by Robert Orlowski
Blog
Jan 20, 2025, 12:26
The first seminar of 2025 NCI Rising Scholars: Cancer Research Seminar Series
Blog
Jan 20, 2025, 12:16
Rita A. Sakr: Honored to present dear breast cancer survivors at SABCS24
Blog
Jan 20, 2025, 12:11
Catharine Young: Real progress doesn’t happen in isolation
Blog
Jan 20, 2025, 11:28
Fernanda Rivera's Journey as the first Mexican RadOnc Resident to receive the ASCO IDEA Award
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research